Navigation Links
Proteomic analysis of immunocamouflaged surfaces

The transfusion of red blood cells (RBC) is a critical component in the treatment of a number of acute and chronic medical problems. Indeed, approximately 75 million units of whole blood (~34 million liters) are annually collected worldwide for processing and eventual transfusion. Despite this massive collection effort, the need for blood constantly exceeds availability due to a combination of collection, manufacturing, storage and biological (i.e., immunological) issues. The immunological issues can often be the most clinically vexing as the RBC has ~300 blood group antigens that could potentially result in alloimmunization and, in rare cases, prevent life saving transfusions. Currently, there are limited options to either prevent blood group alloimmunization or to cost-effectively treat patients with severe alloimmunization.

To this end, the bioengineering of RBCs by the grafting of biocompatible polymers, such as methoxypoly(ethylene glycol) (mPEG), to donor cells is a promising non-pharmacological immunomodulation technology for preventing RBC transfusion reactions. However, due to the labile nature of RBCs, surface-plasma interactions are poorly understood. To overcome the limitations imposed by viable cells, Dr. Mark Scott and his colleagues at the Canadian Blood Services and the University of British Columbia examined plasma adsorption to bare and polymer modified latex beads using fluorescently labeled plasma and proteomic techniques. Their work, entitled "Immunocamouflage of latex surfaces by grafted methoxypoly(ethylene glycol) (mPEG): proteomic analysis of plasma protein adsorption", was published in SCIENCE CHINA Life Sciences 55 (3), 191-201 (2012).

The authors reported that covalent grafting of mPEG to latex beads gave rise to global immunocamouflage of the bead surface resulting in decreased plasma protein adsorption as assessed by flow cytometry, gel electrophoresis and advanced proteomic analysis using isobaric tags for relative and absolute quantitation (iTRAQ) labeling followed by mass spectrometry (MS). The reduction in plasma adsorption occurred because of polymer-mediated thermodynamic steric exclusion and surface charge camouflage. The iTRAQ-MS findings also demonstrated that the grafted polymer prevented surface interactions with plasma proteins involved in the immune recognition of biomaterials and allogeneic cells.

Biologically, the reduced surface-plasma interactions would enhance biocompatibility by camouflaging antigenic sites and preventing the generation of immune recognition signals. The findings of this paper are supportive and predictive of previously reported observations of the immunocamouflage of RBCs and lymphocytes and of the prevention of viral invasion of cells. The knowledge derived from these proteomic studies will help to further define the physical and chemical parameters necessary for efficient immunocamouflage of allogeneic cells, tissues and biomaterials. The practical application of the immunocamouflage technology could have a significant impact on improving the safety of donor cells (e.g., RBCs), tissues and implantable biomaterials in clinical medicine.

Qualitative and quantitative analysis of plasma surface interactions demonstrated the efficacy of immunocamouflage in preventing plasma protein adsorption. Moreover, iTRAQ analysis provided clear evidence for reduced adsorption of proteins associated with the immunological recognition of foreign cells/tissues and biomaterials.

Contact: Mark D. SCOTT
Science in China Press

Related biology news :

1. AMP opposes exclusive licensing of NIH proteomics patent
2. TGens Center for Proteomics selected as Waters Center of Innovation
3. Case Western Reserve and NeoProteomics announce exclusive option
4. Reportlinker Adds Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics
5. GEN reports on rediscovered technology to bolster proteomics research
6. Protein extremes gain relevance in massive proteomic studies
7. KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification
8. Reportlinker Adds Proteomics: Technologies and Global Markets Report
9. Proteomics: Finding the key ingredients of disease
10. New manual presents robust, state-of-the-art proteomics methods for teaching and research
11. Proteomics study yields clues as to how tuberculosis might be thwarting the immune system
Post Your Comments:
Related Image:
Proteomic analysis of immunocamouflaged surfaces
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology: